New Platform Analyzes Patients Genomic Biomarkers to Match with Available Clinical Trials Nationwide

Share
Facebook
Twitter
Pinterest
LinkedIn
Email
Print

UH Seidman Cancer Center has streamlined the process for connecting our patients to clinical trials through an innovative new partnership with GenomOncology, a Cleveland-based biotechnology company that creates software-based solutions for precision oncology. With a new proprietary platform, our clinicians can help patients more quickly find all available clinical trials across the country that apply to their diagnosis.

The continued evolution of precision oncology has made it more challenging for physicians and patients to see all curated biomarker-based and institutional non-biomarker clinical trials. By partnering with GenomOncology to automate patient analysis and treatment matching, UH can effectively and efficiently match patients to therapies and relevant, open clinical trials. This solution provides UH with the capability to identify cohorts of patients eligible for clinical trials and novel therapies, as well as the ability to perform feasibility analysis for opening new clinical trials across all UH Seidman Cancer Center wholly-owned locations.

UH will utilize GenomOncology’s GO Connect solution to pull information from our clinical care systems. Precision Decision will match patients with relevant clinical trials and therapies. The information is synthesized into a single dashboard, which gives clinicians the option to search for UH patients who could be eligible to enroll in open clinical trials, as well as those who may qualify for a newly approved therapy. The solution also enables our teams to examine our internal database of patients’ clinical and molecular profiles to determine the feasibility of opening new clinical trials.

This partnership establishes a new paradigm for patient care. Due to the speed and complexity of genetic and biomarker discoveries, it is virtually impossible for any oncologist to remain current on all the clinical trials and newly approved cancer therapies. Through this partnership with GenomOncology, we have leveraged the power of computing to process incredible amounts of data and identify the optimal care for every patient.

Share
Facebook
Twitter
Pinterest
LinkedIn
Email
Print